We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

44 hedge funds and large institutions have $18M invested in Matinas BioPharma in 2017 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,021% more capital inflows, than outflows

Capital inflows: $23.9M | Capital outflows: $2.13M

357% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 7

132% more funds holding

Funds holding: 19 → 44 (+25)

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

8.8% more ownership

Funds ownership: 2.82% → 11.63% (+8.8%)

Holders
44
Holders Change
+25
Holders Change %
+131.58%
% of All Funds
1.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
32
Increased
5
Reduced
4
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$6.57M
2
BlackRock
BlackRock
New York
+$6.43M
3
IFP Advisors
IFP Advisors
Florida
+$1.88M
4
State Street
State Street
Massachusetts
+$1.79M
5
Northern Trust
Northern Trust
Illinois
+$1.55M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$691K
2
Goldman Sachs
Goldman Sachs
New York
-$566K
3
Segantii Capital Management
Segantii Capital Management
Hong Kong
-$166K
4
Morgan Stanley
Morgan Stanley
New York
-$155K
5
Spark Investment Management
Spark Investment Management
New York
-$105K

MTNB Hedge Fund Activity: Q2 2017 in Review

44 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q2 2017, worth a combined $18M — up 156% from $7.01M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new MTNB positions and 7 closed out — a net gain of 25 holders — while 5 added to existing stakes and 4 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $6.57M. The largest seller was Millennium Management, cutting an estimated $691K.

  • 44 institutional investors held Matinas BioPharma (MTNB) as of Q2 2017, up from 19 in Q1 2017.
  • Funds reported $18M of Matinas BioPharma stock for Q2 2017, up 156% quarter-over-quarter.
  • 32 funds opened new Matinas BioPharma positions in Q2 2017 and 7 closed out, a net change of +25 holders.
  • The largest Matinas BioPharma buyer in Q2 2017 was Vanguard Group, an estimated $6.57M added.
  • The largest Matinas BioPharma seller in Q2 2017 was Millennium Management, an estimated $691K sold.

Based on aggregated 13F filings for Q2 2017.